Beobachten
- Pressemitteilung BoxID 504264
4SC receives milestone payment from research collaboration with SKK
(PresseBox) (Planegg-Martinsried, Germany, )
4SC AG (Frankfurt, Prime Standard: VSC), a discovery and development company of targeted small molecule drugs for autoimmune diseases and cancer, today announced that it has received a milestone payment from the Japanese pharmaceutical company Sanwa Kagaku Kenkyusho Co. Ltd., Nagoya (SKK) under a previously-concluded research collaboration.
The milestone payment will go to 4SC Discovery GmbH, a wholly-owned subsidiary of 4SC AG specialising in the early-stage biopharmaceutical research and discovery of new drug substances.
Under the research collaboration, 4SC had contributed its know-how in the field of medicinal chemistry together with its expertise in computerised (in silico) screening and modelling for the rapid discovery, selection and optimisation of new drug substances (hits and leads) to investigate new classes of substances for the potential therapy of metabolic diseases. In its pharmaceutical research and development work, SKK has now achieved decisive progress with an optimised chemical compound resulting from this collaboration, which triggered the contractually-agreed milestone payment.
Dr. Daniel Vitt, Chief Scientific Officer of 4SC AG and Managing Director of 4SC Discovery GmbH commented: 'We are very pleased to have received this milestone payment. This success further stresses our long-standing research expertise and the capabilities of our core technology for the discovery and optimisation of new pharmaceutical compounds, a technology that we have been marketing more actively since early 2012 with the newly-launched 4SC Discovery. Our special thanks are due to our partner SKK for the fruitful and pleasant collaboration. We intend to use this and, in the future, similar ventures to further strengthen the business of both 4SC Discovery and the entire 4SC Group.'
About SKK
Sanwa Kagaku Kenkyusho Co., Ltd. (SKK) is a fully-integrated pharmaceutical company headquartered in Nagoya, Japan. Their business is concentrated in research and development, manufacture, and sales of ethical pharmaceuticals, diagnostics, medical foods, health care products and contract manufacturing of pharmaceuticals. SKK's targeted therapeutic areas are metabolic disorders, renal diseases and ophthalmic diseases. Further information is available at: http://www.skk-net.com/en/
Legal Note
This document may contain projections or estimates relating to plans and objectives relating to our future operations, products, or services; future financial results; or assumptions underlying or relating to any such statements; each of which constitutes a forward-looking statement subject to risks and uncertainties, many of which are beyond our control. Actual results could differ materially, depending on a number of factors.
For more information please visit www.4sc.com and www.4sc-discovery.com
The milestone payment will go to 4SC Discovery GmbH, a wholly-owned subsidiary of 4SC AG specialising in the early-stage biopharmaceutical research and discovery of new drug substances.
Under the research collaboration, 4SC had contributed its know-how in the field of medicinal chemistry together with its expertise in computerised (in silico) screening and modelling for the rapid discovery, selection and optimisation of new drug substances (hits and leads) to investigate new classes of substances for the potential therapy of metabolic diseases. In its pharmaceutical research and development work, SKK has now achieved decisive progress with an optimised chemical compound resulting from this collaboration, which triggered the contractually-agreed milestone payment.
Dr. Daniel Vitt, Chief Scientific Officer of 4SC AG and Managing Director of 4SC Discovery GmbH commented: 'We are very pleased to have received this milestone payment. This success further stresses our long-standing research expertise and the capabilities of our core technology for the discovery and optimisation of new pharmaceutical compounds, a technology that we have been marketing more actively since early 2012 with the newly-launched 4SC Discovery. Our special thanks are due to our partner SKK for the fruitful and pleasant collaboration. We intend to use this and, in the future, similar ventures to further strengthen the business of both 4SC Discovery and the entire 4SC Group.'
About SKK
Sanwa Kagaku Kenkyusho Co., Ltd. (SKK) is a fully-integrated pharmaceutical company headquartered in Nagoya, Japan. Their business is concentrated in research and development, manufacture, and sales of ethical pharmaceuticals, diagnostics, medical foods, health care products and contract manufacturing of pharmaceuticals. SKK's targeted therapeutic areas are metabolic disorders, renal diseases and ophthalmic diseases. Further information is available at: http://www.skk-net.com/en/
Legal Note
This document may contain projections or estimates relating to plans and objectives relating to our future operations, products, or services; future financial results; or assumptions underlying or relating to any such statements; each of which constitutes a forward-looking statement subject to risks and uncertainties, many of which are beyond our control. Actual results could differ materially, depending on a number of factors.
For more information please visit www.4sc.com and www.4sc-discovery.com
Über 4SC AG
The Group (4SC) managed by 4SC AG (ISIN DE0005753818) discovers and develops targeted, small-molecule drugs for treating diseases with a high unmet medical need in various autoimmune and cancer indications. These drugs are intended to provide innovative treatment options that are more tolerable and efficacious than existing therapies, and provide a better quality of life. 4SC AG, as the Group parent company, is concentrating on the clinical development of the drugs and their commercialisation together with pharmaceutical partners. 4SC Discovery GmbH, the fully-owned subsidiary of 4SC AG, is focused on the research and discovery of new therapeutic compounds - a measure also intended to further enhance the clinical development pipeline of 4SC AG - as well as their early-stage commercialisation. In addition, 4SC Discovery enters into service and collaboration agreements with pharmaceutical and biotech partners in the field of drug discovery. 4SC was established in 1997 and had 96 employees at the end of 2011. 4SC AG has been listed on the Prime Standard at the Frankfurt Stock Exchange since December 2005.
Diese Pressemitteilungen könnten Sie auch interessieren
|
Abverkäufe auf breiter Front
, Finanzen / Bilanzen, CeFDex AG
"Obwohl nach dem gestrigen FOMC Meeting keine eindeutigen Prognosen für die zukünftige Zinspolitik der FED abgeleitet werden konnten, ging es nach 20:15 Uhr auf...
|
Marktgeflüster: Zu viel Optimismus?
, Finanzen / Bilanzen, actior AG
Seit einer Woche haben sich die Märkte beruhigt und gehen davon aus, daß die Fed mit der Drosselung der Liquidität noch warten wird. Das ist aber möglicherweise...
|
Anlegerirrtümer können teuer werden – lassen sich aber leicht vermeiden
, Finanzen / Bilanzen, Financial Planning Standards Board Deutschland e.V.
Geld anzulegen ist in diesen unruhigen Zeiten am Kapitalmarkt gar keine einfache Sache. Aber dass viele Privatinvestoren immer dieselben Fehler machen, ist schwer...
